March 20, 2011

JEVTANA® (cabazitaxel) Approved by European Commission for Treatment of Advanced Second-line Prostate Cancer

– Life-extending treatment for mHRPC patients approved throughout Europe –

 

JEVTANA® (cabazitaxel) Approved by European Commission for Treatment of Advanced Second-line Prostate Cancer
– Life-extending treatment for mHRPC patients approved throughout Europe –

Paris, France – March 20, 2011 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today it has received marketing authorization from the European Commission for JEVTANA® (cabazitaxel) in combination with prednisone/prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen.1 JEVTANA is the first approved agent to significantly extend overall survival in mHRPC patients whose disease has progressed during or after treatment containing docetaxel (15.1 months median overall survival vs 12.7 months in the mitoxantrone arm; HR=0.70 (95% CI: 0.59-0.83); P<0.0001).1